FDA Drug Recalls
17,898 recalls, newest first
Class I · High risk Ongoing Jul 17, 2025
Reason Microbial Contamination of Non-Sterile Drug Product: The products were found to be contaminated with the bacteria Burkholderia cepecia.
Class I · High risk Ongoing Jul 17, 2025
Reason Microbial Contamination of Non-Sterile Drug Product: The products were found to be contaminated with the bacteria Burkholderia cepecia.
Class II · Moderate risk Ongoing Jul 15, 2025
Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit
Class II · Moderate risk Ongoing Jul 11, 2025
Reason CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot…
Class II · Moderate risk Ongoing Jul 10, 2025
Reason CGMP Deviations
Class II · Moderate risk Ongoing Jul 10, 2025
Reason CGMP Deviations
Class II · Moderate risk Ongoing Jul 10, 2025
Reason CGMP Deviations
Class II · Moderate risk Ongoing Jul 10, 2025
Reason CGMP Deviations; particulates identified during visual inspection
Class II · Moderate risk Ongoing Jul 10, 2025
Reason CGMP Deviations; particulates identified during visual inspection
Class II · Moderate risk Ongoing Jul 9, 2025
Reason Subpotent Drug
Class II · Moderate risk Ongoing Jul 9, 2025
Reason Subpotent Drug
Class III · Low risk Ongoing Jul 9, 2025
Reason Subpotent Drug
Class II · Moderate risk Ongoing Jul 9, 2025
Reason Subpotent Drug
Class II · Moderate risk Ongoing Jul 9, 2025
Reason Failed Dissolution Specifications.
Class III · Low risk Completed Jul 9, 2025
Reason Sub-Potent Drug: Subpotent assay results during stability testing.
Class II · Moderate risk Completed Jul 9, 2025
Reason Sub-Potent Drug: Subpotent assay results during stability testing.
Class II · Moderate risk Ongoing Jul 9, 2025
Reason CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
Class II · Moderate risk Ongoing Jul 9, 2025
Reason CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
Class II · Moderate risk Ongoing Jul 7, 2025
Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.
Class II · Moderate risk Ongoing Jul 7, 2025
Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.
Class II · Moderate risk Ongoing Jul 7, 2025
Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.
Class II · Moderate risk Ongoing Jul 7, 2025
Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.
Class II · Moderate risk Ongoing Jul 7, 2025
Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.
Class II · Moderate risk Ongoing Jul 7, 2025
Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.
Class II · Moderate risk Ongoing Jul 5, 2025
Reason Defective Container: spike of the cap becomes lodged in the nozzle of the product bottle.